Amgen (NASDAQ:AMGN) Stock Keeps "Overweight" Rating at Piper Sandler

Amgen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Piper Sandler reaffirmed its Overweight rating on Amgen and raised its price target from $457 to $542, implying 22.9% upside from the stock’s then-current price.
  • Analyst sentiment overall is more cautious: MarketBeat reports an average Hold rating and a $428.62 average price target, below Amgen’s Thursday price of $441.01.
  • Amgen beat quarterly earnings and revenue expectations, reporting EPS of $6.45 versus $5.79 expected and revenue up 8.5% year over year to $10.37 billion.
  • Five stocks we like better than Amgen.

Amgen (NASDAQ:AMGN - Get Free Report)'s stock had its "overweight" rating reaffirmed by equities research analysts at Piper Sandler in a note issued to investors on Thursday, Benzinga reports. They presently have a $542.00 target price on the medical research company's stock, up from their previous target price of $457.00. Piper Sandler's price target indicates a potential upside of 22.90% from the stock's current price.

Other research analysts have also recently issued research reports about the stock. Oppenheimer reiterated an "outperform" rating on shares of Amgen in a report on Friday, October 23rd. Canaccord Genuity Group lifted their price objective on shares of Amgen from $384.00 to $440.00 and gave the stock a "hold" rating in a research report on Wednesday, November 4th. Guggenheim boosted their target price on shares of Amgen from $378.00 to $435.00 and gave the stock a "neutral" rating in a research note on Thursday, November 5th. Weiss Ratings raised Amgen from a "buy (b)" rating to a "buy (b+)" rating in a report on Thursday, October 8th. Finally, UBS Group raised their price target on Amgen from $470.00 to $530.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $428.62.

View Our Latest Research Report on Amgen

Amgen Trading Down 0.6%

Amgen stock traded down $2.88 during midday trading on Thursday, reaching $441.01. 290,264 shares of the stock traded hands, compared to its average volume of 2,733,097. The company has a 50-day simple moving average of $428.15 and a two-hundred day simple moving average of $382.85. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. Amgen has a 12-month low of $312.39 and a 12-month high of $483.99. The firm has a market cap of $238.55 billion, a PE ratio of 25.63, a price-to-earnings-growth ratio of 3.19 and a beta of 0.43.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same period in the prior year, the firm earned $5.64 EPS. The firm's revenue for the quarter was up 8.5% on a year-over-year basis. Research analysts expect that Amgen will post 23.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amgen

Hedge funds have recently made changes to their positions in the company. Wellington Altus USA Inc. grew its stake in Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company's stock worth $28,000 after buying an additional 34 shares during the last quarter. Quest 10 Wealth Builders Inc. boosted its holdings in shares of Amgen by 220.0% in the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company's stock valued at $34,000 after acquiring an additional 55 shares during the period. Nvwm LLC boosted its holdings in shares of Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company's stock valued at $35,000 after acquiring an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Amgen during the second quarter worth approximately $36,000. Finally, PFS Partners LLC grew its position in shares of Amgen by 95.5% during the third quarter. PFS Partners LLC now owns 86 shares of the medical research company's stock worth $36,000 after acquiring an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Company Profile

(Get Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Further Reading

Analyst Recommendations for Amgen (NASDAQ:AMGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amgen Right Now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines